Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04510311 · ClinicalTrials.gov registry record · Early Phase 1
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
A Early Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 32
- Enrollment target
NCT04510311 is a Early Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 32 participants.
The verdict
NCT04510311, a Early Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
The goal of this exploratory study is to test whether \[18F\]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of \[18F\]3F-PHPG as a clinical tool for neuroendocrine tumor localization and staging.
Interventions
- DRUG 3-[18F]Fluoro-para-hydroxyphenethylguanidine
- DRUG [123I] metaiodobenzylguanidine
- DIAGNOSTIC_TEST Positron emission tomography/computed tomography scan
- DIAGNOSTIC_TEST Planar scintigraphy scan
- DIAGNOSTIC_TEST Single photon emission computed tomography/computed tomography scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2024-12-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04510311
The ClinicalTrials.gov registry entry for NCT04510311 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 3-[18F]Fluoro-para-hydroxyphenethylguanidine is the first listed.
NCT04510311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04510311 about?
NCT04510311 is a clinical study titled "Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors". The goal of this exploratory study is to test whether \[18F\]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of \[18F\]3F-PHPG as a clinical tool for neuroendocrine tumor ...
What is the current status of trial NCT04510311?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2020-10-19. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT04510311?
The interventions under investigation include: 3-[18F]Fluoro-para-hydroxyphenethylguanidine (DRUG), [123I] metaiodobenzylguanidine (DRUG), Positron emission tomography/computed tomography scan (DIAGNOSTIC_TEST), Planar scintigraphy scan (DIAGNOSTIC_TEST), Single photon emission computed tomography/computed tomography scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04510311?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.